Top

Osteoporosis International

Published in:

01-10-2017 | Original Article

Atypical subtrochanteric fractures in Korean hip fracture study

Authors: Y.-K. Lee, T.-Y. Kim, Y.-C. Ha, S.-H. Song, J. W. Kim, H. C. Shon, J. S. Chang, K.-H. Koo

Published in: Osteoporosis International | Issue 10/2017

Abstract

Summary

In Korean, atypical subtrochanteric fractures (ASF) were rare. Higher BMI and use of bisphosphonate were significant risk factors of ASF.

Introduction

Recently, ASF have been reported to increase among patients on bisphosphonate. However, the incidence of ASF and the association between ASF and bisphosphonate use have not been well defined in Asian population. Our purposes are (1) to estimate the proportion of ASF among Korean patients with proximal femur fracture and (2) to determine the associated risk factors of ASF in the Korean patients.

Methods

We conducted a multicenter (16 academic hospitals), prospective Korean hip fracture study on hip fracture in a cohort of patients aged 50 years or older from South Korea between July 2014 and May 2016. As a part of Korean hip fracture study, primary analysis examined the proportion of ASF among proximal femur fracture. To identify ASF, according to the definition by ASBMR task force, all radiographs of subtrochanteric fracture were reviewed. Associated risk factors for occurrence of ASF were also evaluated by using multivariable logistic regression analysis.

Results

Among 1361 patients with proximal femoral fractures due to low-energy trauma, 17 fractures (1.2%) were identified as ASF. Higher BMI and use of bisphosphonate before injury were independent risk factors of ASF.

Conclusion

In Korean, ASF were rare. Higher BMI and use of bisphosphonate were significant risk factors of ASF.

Wang Z, Ward MM, Chan L, Bhattacharyya T (2014) Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries. Osteoporos Int 25:2109–2116CrossRefPubMedPubMedCentral

Wang Z, Bhattacharyya T (2011) Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996–2007. J Bone Miner Res 26:553–560CrossRefPubMed

Schilcher J, Aspenberg P (2009) Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop 80:413–415CrossRefPubMedPubMedCentral

Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO, Zhou H, Burchette RJ, Ott SM (2012) Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 27:2544–2550CrossRefPubMed

Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, Whelan DB, Weiler PJ, Laupacis A (2011) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305:783–789CrossRefPubMed

Abrahamsen B, Eiken P, Prieto-Alhambra D, Eastell R (2016) Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. BMJ 353:i3365CrossRefPubMedPubMedCentral

Lee YK, Ha YC, Park C, Yoo JJ, Shin CS, Koo KH (2013) Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry. Osteoporos Int 24:707–711CrossRefPubMed

Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267–2294CrossRefPubMed

Rizzoli R, Akesson K, Bouxsein M, Kanis JA, Napoli N, Papapoulos S, Reginster JY, Cooper C (2011) Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 22:373–390CrossRefPubMed

10.

Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Howe TS, van der Meulen MC, Weinstein RS, Whyte MP (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1–23CrossRefPubMed

11.

Koval KJ, Aharonoff GB, Rosenberg AD, Bernstein RL, Zuckerman JD (1998) Functional outcome after hip fracture. Effect of general versus regional anesthesia. Clin Orthop Relat Res 37–41.

12.

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRefPubMed

13.

Koeppen VA, Schilcher J, Aspenberg P (2013) Dichotomous location of 160 atypical femoral fractures. Acta Orthop 84:561–564CrossRefPubMedPubMedCentral

14.

Giusti A, Hamdy NA, Dekkers OM, Ramautar SR, Dijkstra S, Papapoulos SE (2011) Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone 48:966–971CrossRefPubMed

15.

Abrahamsen B, Clark EM (2012) Disentangling the emerging evidence around atypical fractures. Curr Rheumatol Rep 14:212–216CrossRefPubMed

16.

Kim D, Sung YK, Cho SK, Han M, Kim YS (2016) Factors associated with atypical femoral fracture. Rheumatol Int 36:65–71CrossRefPubMed

17.

Saita Y, Ishijima M, Mogami A, Kubota M, Baba T, Kaketa T, Nagao M, Sakamoto Y, Sakai K, Homma Y, Kato R, Nagura N, Miyagawa K, Wada T, Liu L, Matsuoka J, Obayashi O, Shitoto K, Nozawa M, Kajihara H, Gen H, Kaneko K (2015) The incidence of and risk factors for developing atypical femoral fractures in Japan. J Bone Miner Metab 33:311–318CrossRefPubMed

18.

Pedrazzoni M, Giusti A, Girasole G, Abbate B, Verzicco I, Cervellin G (2016) Atypical femoral fractures in Italy: a retrospective analysis in a large urban emergency department during a 7-year period (2007–2013). J Bone Miner Metab. doi:10.1007/s00774-016-0790-7

19.

Juby AG, Crowther S, Cree M (2014) Identifying atypical femoral fractures—a retrospective review. Calcif Tissue Int 95:405–412CrossRefPubMed

20.

Kim SY, Schneeweiss S, Katz JN, Levin R, Solomon DH (2011) Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res 26:993–1001CrossRefPubMed

21.

Abrahamsen B, Eiken P, Eastell R (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24:1095–1102CrossRefPubMed

22.

Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294–1301CrossRefPubMed

23.

Meling T, Nawab A, Harboe K, Fosse L (2014) Atypical femoral fractures in elderly women: a fracture registry-based cohort study. Bone Joint J 96-b:1035–1040CrossRefPubMed

24.

Schilcher J, Michaelsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364:1728–1737CrossRefPubMed

25.

Ettinger B, Stuenkel CA, Schnatz PF (2013) Menopause practitioner perspective on the American Society of Bone and Mineral Research Task Force report on atypical femoral fracture. Menopause (New York, NY) 20:1092-1097.

26.

Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ, Greenspan SL, McKinney R Jr, Pignolo RJ, Sellmeyer DE (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 31:16–35CrossRefPubMedPubMedCentral

Title: Atypical subtrochanteric fractures in Korean hip fracture study
Authors: Y.-K. Lee
T.-Y. Kim
Y.-C. Ha
S.-H. Song
J. W. Kim
H. C. Shon
J. S. Chang
K.-H. Koo
Publication date: 01-10-2017
Publisher: Springer London
Published in: Osteoporosis International / Issue 10/2017
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-017-4112-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Atypical subtrochanteric fractures in Korean hip fracture study

Abstract

Summary

Introduction

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2017

Value and potential limitations of vertebral fracture assessment (VFA) compared to conventional spine radiography: experience from a fracture liaison service (FLS) and a meta-analysis

Skeletal complications of rheumatoid arthritis

Diversity in fall characteristics hampers effective prevention: the precipitants, the environment, the fall and the injury

Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures

Osteoporosis exercise knowledge and education in medicine and nursing: response to comments by Nguyen

One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study